Public

Environmental and Social Data Sheet

Overview

Project Name:	MEDIAN TECHNOLOGIES (EGFF)
Project Number:	2018-0347
Country:	France

Project Description: The promoter is a company developing Artificial Intelligence based imaging platform for medical image analysis, to be further used in different biopharma and healthcare applications. The purpose of the Company is to help to better diagnose, monitor and treat patients with cancers and other chronic diseases, and support the development of personalised therapies.

EIA required: no

Project included in Carbon Footprint Exercise[1]: no

(details for projects included are provided in section: "EIB Carbon Footprint Exercise")

Environmental and Social Assessment

Environmental Assessment

The Promoter's investments that will be financed through this operation concern research, development and innovation activities carried out in the medtech sector. More specifically, it will support Median's efforts to develop medical images software using artificial intelligence, cloud computing and big data to be used by the biopharma and healthcare providers. The Company's purpose is to help better diagnose, monitor and treatment of patients with chronic diseases and support the implementation of personalised therapies.

The Project activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU and are considered environmentally not harmful. Moreover, the Project will be carried out in existing facilities already authorised for similar activities and volumes.

The Promoter's RDI practices are in compliance with relevant national and EU regulations (directives 2001/20/EC and 2005/28/EC, as applicable) and the Promoter maintains adequate internal procedures and management practices. The Promoter's Quality Management System is EN ISO 13485:2012 certified ensuring that Company's medical devices and related services consistently meet customer requirements and applicable regulatory requirements.

---

[1] Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO2e/year absolute (gross) or 20,000 tonnes CO2e/year relative (net) – both increases and savings.

Social Assessment, where applicable

If successful, the project is expected to lead to important social benefits stemming from its focus on the development of novel diagnosis and personalised therapies for diseases associated with substantial social and economic impact. The Company's development will allow maintaining and / or further enhancing European competencies and skills in an area of strategic importance for Europe, i.e. artificial intelligence.

Conclusions and Recommendations

If successful, the project presents potentially high health and societal benefits for the wider society. Considering the above, the project is deemed acceptable for the Bank's financing under environmental and social terms.

PJ/SQM/ECSO 01.02.2019